子宫内膜异位症的血清代谢分析揭示了腹膜子宫内膜异位症的强烈代谢特征

IF 6 1区 医学 Q1 OBSTETRICS & GYNECOLOGY
R Kollarics, D M Selegato, A Marshall, J Jauckus, T Strowitzki, M Zimmermann, A Germeyer
{"title":"子宫内膜异位症的血清代谢分析揭示了腹膜子宫内膜异位症的强烈代谢特征","authors":"R Kollarics, D M Selegato, A Marshall, J Jauckus, T Strowitzki, M Zimmermann, A Germeyer","doi":"10.1093/humrep/deaf097.081","DOIUrl":null,"url":null,"abstract":"Study question What are the metabolome differences between the serum of patients with endometriosis and control subjects? What metabolic traits are characteristic of peritoneal and/or ovarian endometriosis? Summary answer Endometriosis patients have high abundance of riboflavin, tryptophan and purine metabolites in serum. Peritoneal endometriosis has stronger metabolic signature than ovarian endometriosis compared to controls. What is known already Endometriosis patients exhibit different metabolic traits compared to healthy subjects. Several metabolomics studies were conducted on different types of samples (serum, plasma, peritoneal fluid, follicular fluid, eutopic/ectopic endometrial tissue, urine, cervical swabs). However, the sample sizes are limited, and inclusion/exclusion criteria vary. Alterations in amino acid levels, (phospho)lipid metabolites, and purine metabolites are described, though results are controversial depending on sample type and study design. Currently, there is no biomarker for endometriosis and its pathomechanism is still unclear. Study design, size, duration Serum samples were obtained before surgery from 338 dysmenorrheic and/or infertile patients undergoing laparoscopic surgery at a university-affiliated fertility center from February 2019 to October 2024. Patients with hormonal treatment, psychiatric medication, immunosuppressive treatment, hyperthyroidism, autoimmune diseases, hyperprolactinaemia, malignancy, systemic diseases, liver-, kidney diseases, and infection were excluded. Patients were divided into groups based on their laparoscopic diagnosis: peritoneal endometriosis (PE, n = 61), ovarian endometriosis (OE, n = 33), or control group (n = 87). Participants/materials, setting, methods Peritoneal group included ASRM I-II (#Enzian P1-2, O0, T0-2), ovarian group included ASRMI-IV (#Enzian P0-3, O1-2, T0-1) endometriosis stages. Controls had a negative laparoscopic diagnosis for endometriosis. Metabolite profiles were investigated by liquid chromatography (UHPLC-MS) coupled with high-resolution mass spectrometry. Semitargeted and untargeted metabolomics analyses were performed. Semitargeted analysis monitored around 50 metabolites, including vitamins, amino acids, sugar, tryptophan-derivates, and nucleotides. Statistical analyses were conducted to identify metabolic differences between endometriosis patients and controls. Main results and the role of chance Endometriosis groups (PE, OE) have different metabolic profiles compared to symptomatic controls. Interestingly, PE group is well-separated metabolically from both the control and OE groups. OE group shows an intermediate metabolic profile between PE and control groups. Peritoneal endometriosis has a stronger metabolic signature than ovarian endometriosis. Semitargeted analysis revealed significant metabolic alterations in the tryptophan and riboflavin pathways, including kynurenines, indols, and riboflavin intermediates. Limitations, reasons for caution A dietary questionnaire was not conducted among patients. No information is available on the diet of patients, which could alter their metabolic profiles. The #Enzian score was established in 2021; we evaluated it retrospectively for older samples based on the operation reports. Wider implications of the findings A well-described metabolic signature of endometriosis might allow the identification of early biomarkers for endometriosis. It could also give deeper insight into the pathomechanism of the disease. Furthermore, it might provide hypotheses for designing nutritional interventions to prevent progression or reduce postoperative recurrence of endometriosis. Trial registration number Yes","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"1 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O-081 Serum metabolic profiling in endometriosis reveals a strong metabolic signature for peritoneal endometriosis\",\"authors\":\"R Kollarics, D M Selegato, A Marshall, J Jauckus, T Strowitzki, M Zimmermann, A Germeyer\",\"doi\":\"10.1093/humrep/deaf097.081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Study question What are the metabolome differences between the serum of patients with endometriosis and control subjects? What metabolic traits are characteristic of peritoneal and/or ovarian endometriosis? Summary answer Endometriosis patients have high abundance of riboflavin, tryptophan and purine metabolites in serum. Peritoneal endometriosis has stronger metabolic signature than ovarian endometriosis compared to controls. What is known already Endometriosis patients exhibit different metabolic traits compared to healthy subjects. Several metabolomics studies were conducted on different types of samples (serum, plasma, peritoneal fluid, follicular fluid, eutopic/ectopic endometrial tissue, urine, cervical swabs). However, the sample sizes are limited, and inclusion/exclusion criteria vary. Alterations in amino acid levels, (phospho)lipid metabolites, and purine metabolites are described, though results are controversial depending on sample type and study design. Currently, there is no biomarker for endometriosis and its pathomechanism is still unclear. Study design, size, duration Serum samples were obtained before surgery from 338 dysmenorrheic and/or infertile patients undergoing laparoscopic surgery at a university-affiliated fertility center from February 2019 to October 2024. Patients with hormonal treatment, psychiatric medication, immunosuppressive treatment, hyperthyroidism, autoimmune diseases, hyperprolactinaemia, malignancy, systemic diseases, liver-, kidney diseases, and infection were excluded. Patients were divided into groups based on their laparoscopic diagnosis: peritoneal endometriosis (PE, n = 61), ovarian endometriosis (OE, n = 33), or control group (n = 87). Participants/materials, setting, methods Peritoneal group included ASRM I-II (#Enzian P1-2, O0, T0-2), ovarian group included ASRMI-IV (#Enzian P0-3, O1-2, T0-1) endometriosis stages. Controls had a negative laparoscopic diagnosis for endometriosis. Metabolite profiles were investigated by liquid chromatography (UHPLC-MS) coupled with high-resolution mass spectrometry. Semitargeted and untargeted metabolomics analyses were performed. Semitargeted analysis monitored around 50 metabolites, including vitamins, amino acids, sugar, tryptophan-derivates, and nucleotides. Statistical analyses were conducted to identify metabolic differences between endometriosis patients and controls. Main results and the role of chance Endometriosis groups (PE, OE) have different metabolic profiles compared to symptomatic controls. Interestingly, PE group is well-separated metabolically from both the control and OE groups. OE group shows an intermediate metabolic profile between PE and control groups. Peritoneal endometriosis has a stronger metabolic signature than ovarian endometriosis. Semitargeted analysis revealed significant metabolic alterations in the tryptophan and riboflavin pathways, including kynurenines, indols, and riboflavin intermediates. Limitations, reasons for caution A dietary questionnaire was not conducted among patients. No information is available on the diet of patients, which could alter their metabolic profiles. The #Enzian score was established in 2021; we evaluated it retrospectively for older samples based on the operation reports. Wider implications of the findings A well-described metabolic signature of endometriosis might allow the identification of early biomarkers for endometriosis. It could also give deeper insight into the pathomechanism of the disease. Furthermore, it might provide hypotheses for designing nutritional interventions to prevent progression or reduce postoperative recurrence of endometriosis. Trial registration number Yes\",\"PeriodicalId\":13003,\"journal\":{\"name\":\"Human reproduction\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human reproduction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/humrep/deaf097.081\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human reproduction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/humrep/deaf097.081","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究问题子宫内膜异位症患者与对照组血清代谢组差异是什么?腹膜和/或卵巢子宫内膜异位症的代谢特征是什么?结论子宫内膜异位症患者血清中核黄素、色氨酸和嘌呤代谢产物含量较高。与对照组相比,腹膜子宫内膜异位症比卵巢子宫内膜异位症具有更强的代谢特征。众所周知,与健康受试者相比,子宫内膜异位症患者表现出不同的代谢特征。对不同类型的样本(血清、血浆、腹膜液、卵泡液、异位/异位子宫内膜组织、尿液、宫颈拭子)进行了几项代谢组学研究。然而,样本量有限,纳入/排除标准各不相同。氨基酸水平、(磷)脂质代谢物和嘌呤代谢物的改变被描述,尽管结果是有争议的,这取决于样本类型和研究设计。目前,尚无子宫内膜异位症的生物标志物,其发病机制尚不清楚。研究设计、规模、持续时间2019年2月至2024年10月,在某大学附属生育中心接受腹腔镜手术的338例痛经和/或不孕症患者术前采集血清样本。排除激素治疗、精神药物治疗、免疫抑制治疗、甲状腺功能亢进、自身免疫性疾病、高泌乳素血症、恶性肿瘤、全身性疾病、肝脏、肾脏疾病和感染的患者。根据腹腔镜诊断将患者分为腹膜子宫内膜异位症(PE, n = 61)、卵巢子宫内膜异位症(OE, n = 33)和对照组(n = 87)。腹膜组包括ASRM I-II (#Enzian P1-2, 0, T0-2),卵巢组包括ASRM iv (#Enzian P0-3, 01 -2, T0-1)子宫内膜异位症分期。对照组腹腔镜诊断子宫内膜异位症阴性。采用液相色谱-质谱联用高分辨率质谱法研究代谢物谱。进行了半靶向和非靶向代谢组学分析。半靶向分析监测了大约50种代谢物,包括维生素、氨基酸、糖、色氨酸衍生物和核苷酸。通过统计分析确定子宫内膜异位症患者和对照组之间的代谢差异。主要结果和机会的作用子宫内膜异位症组(PE, OE)有不同的代谢谱与症状对照。有趣的是,PE组在代谢方面与对照组和OE组都有很好的分离。OE组代谢谱介于PE组和对照组之间。腹膜子宫内膜异位症比卵巢子宫内膜异位症具有更强的代谢特征。半靶向分析揭示了色氨酸和核黄素途径的显著代谢改变,包括犬尿氨酸、吲哚和核黄素中间体。局限性和谨慎的原因没有在患者中进行饮食问卷调查。没有关于患者饮食的信息,这可能会改变他们的代谢谱。#Enzian评分于2021年建立;我们根据手术报告对旧样本进行回顾性评估。对子宫内膜异位症代谢特征的良好描述可能有助于确定子宫内膜异位症的早期生物标志物。它还可以更深入地了解这种疾病的病理机制。此外,这可能为设计营养干预措施以预防进展或减少子宫内膜异位症术后复发提供假设。试验注册号是
本文章由计算机程序翻译,如有差异,请以英文原文为准。
O-081 Serum metabolic profiling in endometriosis reveals a strong metabolic signature for peritoneal endometriosis
Study question What are the metabolome differences between the serum of patients with endometriosis and control subjects? What metabolic traits are characteristic of peritoneal and/or ovarian endometriosis? Summary answer Endometriosis patients have high abundance of riboflavin, tryptophan and purine metabolites in serum. Peritoneal endometriosis has stronger metabolic signature than ovarian endometriosis compared to controls. What is known already Endometriosis patients exhibit different metabolic traits compared to healthy subjects. Several metabolomics studies were conducted on different types of samples (serum, plasma, peritoneal fluid, follicular fluid, eutopic/ectopic endometrial tissue, urine, cervical swabs). However, the sample sizes are limited, and inclusion/exclusion criteria vary. Alterations in amino acid levels, (phospho)lipid metabolites, and purine metabolites are described, though results are controversial depending on sample type and study design. Currently, there is no biomarker for endometriosis and its pathomechanism is still unclear. Study design, size, duration Serum samples were obtained before surgery from 338 dysmenorrheic and/or infertile patients undergoing laparoscopic surgery at a university-affiliated fertility center from February 2019 to October 2024. Patients with hormonal treatment, psychiatric medication, immunosuppressive treatment, hyperthyroidism, autoimmune diseases, hyperprolactinaemia, malignancy, systemic diseases, liver-, kidney diseases, and infection were excluded. Patients were divided into groups based on their laparoscopic diagnosis: peritoneal endometriosis (PE, n = 61), ovarian endometriosis (OE, n = 33), or control group (n = 87). Participants/materials, setting, methods Peritoneal group included ASRM I-II (#Enzian P1-2, O0, T0-2), ovarian group included ASRMI-IV (#Enzian P0-3, O1-2, T0-1) endometriosis stages. Controls had a negative laparoscopic diagnosis for endometriosis. Metabolite profiles were investigated by liquid chromatography (UHPLC-MS) coupled with high-resolution mass spectrometry. Semitargeted and untargeted metabolomics analyses were performed. Semitargeted analysis monitored around 50 metabolites, including vitamins, amino acids, sugar, tryptophan-derivates, and nucleotides. Statistical analyses were conducted to identify metabolic differences between endometriosis patients and controls. Main results and the role of chance Endometriosis groups (PE, OE) have different metabolic profiles compared to symptomatic controls. Interestingly, PE group is well-separated metabolically from both the control and OE groups. OE group shows an intermediate metabolic profile between PE and control groups. Peritoneal endometriosis has a stronger metabolic signature than ovarian endometriosis. Semitargeted analysis revealed significant metabolic alterations in the tryptophan and riboflavin pathways, including kynurenines, indols, and riboflavin intermediates. Limitations, reasons for caution A dietary questionnaire was not conducted among patients. No information is available on the diet of patients, which could alter their metabolic profiles. The #Enzian score was established in 2021; we evaluated it retrospectively for older samples based on the operation reports. Wider implications of the findings A well-described metabolic signature of endometriosis might allow the identification of early biomarkers for endometriosis. It could also give deeper insight into the pathomechanism of the disease. Furthermore, it might provide hypotheses for designing nutritional interventions to prevent progression or reduce postoperative recurrence of endometriosis. Trial registration number Yes
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human reproduction
Human reproduction 医学-妇产科学
CiteScore
10.90
自引率
6.60%
发文量
1369
审稿时长
1 months
期刊介绍: Human Reproduction features full-length, peer-reviewed papers reporting original research, concise clinical case reports, as well as opinions and debates on topical issues. Papers published cover the clinical science and medical aspects of reproductive physiology, pathology and endocrinology; including andrology, gonad function, gametogenesis, fertilization, embryo development, implantation, early pregnancy, genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception, infertility treatment, psychology, ethics and social issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信